Cue Biopharma has developed T-cell modulatory multimeric polypeptides containing an immunomodulatory polypeptide and a Wilms tumor peptide to modulate T cell activity and immune responses. Patent claim 1 describes a homodimer structure with specific amino acid sequences and disulfide bonds for therapeutic applications. GlobalData’s report on Cue Biopharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Cue Biopharma, CAR-T cell based therapies was a key innovation area identified from patents. Cue Biopharma's grant share as of January 2024 was 9%. Grant share is based on the ratio of number of grants to total number of patents.
T-cell modulatory multimeric polypeptides for immune response modulation
See Also:
A recently granted patent (Publication Number: US11878062B2) discloses a novel homodimer structure composed of two heterodimers. Each heterodimer consists of a first polypeptide with a specific amino acid sequence containing a Wilms tumor-1 (WT1) peptide, a ß2-microglobulin (ß2M) polypeptide, and a peptide linker with a Cys residue. The second polypeptide in each heterodimer includes two variant IL-2 polypeptides, a major histocompatibility complex (MHC) class I heavy chain polypeptide, and an immunoglobulin (Ig) Fc polypeptide. The heterodimers are linked by disulfide bonds, with one formed between the Cys residue in the peptide linker and the MHC class I heavy chain polypeptide, and another between Cys residues in the ß2M polypeptide and the MHC class I heavy chain polypeptide. Additionally, two disulfide bonds connect the Ig Fc polypeptide of one heterodimer to the Ig Fc polypeptide of the other heterodimer.
The patent also covers a pharmaceutical composition containing the described homodimer structure, providing potential applications in the field of medicine. This composition offers a unique molecular design that could have implications for therapeutic interventions targeting specific biological pathways or disease mechanisms. The precise arrangement of polypeptides and disulfide bonds in the homodimer structure may offer advantages in terms of stability, efficacy, and targeted delivery of therapeutic agents. Further research and development based on this patented technology could lead to the development of novel pharmaceutical products with enhanced therapeutic properties and improved treatment outcomes for various medical conditions.
To know more about GlobalData’s detailed insights on Cue Biopharma, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
